![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed Reports Second Quarter 2010 Financial Results
August 05, 2010 16:30 ET
|
Depomed, Inc.
MENLO PARK, Calif., Aug. 5, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today reported financial results for the second quarter ended June 30, 2010.
Net income for the three months ended...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed Receives Confirmation from Pfizer That No Infringement Suit to be Filed on DM-1796 NDA
August 03, 2010 16:05 ET
|
Depomed, Inc.
MENLO PARK, Calif., Aug. 3, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that pursuant to the Hatch-Waxman Act, the 45-day period for filing a patent infringement suit under...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed to Announce Second Quarter 2010 Financial Results on August 5, 2010
July 29, 2010 18:08 ET
|
Depomed, Inc.
MENLO PARK, Calif., July 29, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that it will release second quarter 2010 financial results after the market closes Thursday, August 5,...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed Announces Receipt of a $10 Million Milestone Payment for DM-1796
June 28, 2010 17:12 ET
|
Depomed, Inc.
MENLO PARK, Calif., June 28, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that it has received a $10 million milestone payment from Abbott Products, Inc., its licensee of...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed Announces Acceptance of New Drug Application for Investigational Postherpetic Neuralgia Treatment DM-1796
June 07, 2010 16:05 ET
|
Depomed, Inc.
MENLO PARK, Calif., June 7, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that the New Drug Application (NDA) for DM-1796 was accepted by the U.S. Food and Drug Administration...